Published: 19-11-2026 20:16 | Updated: 19-11-2026 20:16

Molecular glues: Unlocking new targets in cancer

Researchers at Karolinska Institutet and the University of Verona in Italy show how expanding the range of E3 ligases used in targeted protein degradation could open new opportunities for treating hard-to-treat cancers. The review is published in the scientific journal Molecular Cell.

The human genome encodes several hundred E3 ligases — the enzymes that decide which proteins a cell destroys. Drug developers have so far harnessed a small number of them. In a new review in Molecular Cell, researchers at Karolinska Institutet and the University of Verona argue that the rest of these E3 ligases are where the next generation of cancer drugs will be found.

Molecular glue degraders are small molecules that rewire the cell’s own degradation machinery to eliminate disease-causing proteins, including ones long considered beyond the reach of drugs. They induce proximity between an E3 ligase and a target protein, marking it for destruction. It is one of the fastest-moving areas in drug discovery today.

“The field has so far relied on only a handful of E3 ligases,” says Andrä Brunner, co-first author of the review. “We map the molecular mechanisms underlying targeted protein degradation and describe how hidden degrons can be exposed and exploited by the many ligases that remain unused. Expanding this repertoire could open new avenues for reaching challenging targets, particularly in hard-to-treat cancers.”

“Knowledge of the interaction interfaces induced by molecular glues that enable an E3 ligase to engage its target is still limited, except for a few well-characterized ligases,” say Daniele Guardavaccaro and Angela Lauriola of the University of Verona. “Consequently, the field has thus far relied on only a small number of ligases for drug discovery and development.”

The review also sets out the framework for a collaboration between the two groups.

“Much of what we describe as untapped is exactly what we are now focusing on. We are working to identify the E3 ligases that could form the basis of the next generation of targeted protein degraders,” says Olle Sangfelt at the Department of Cell and Molecular Biology, Karolinska Institutet.

The collaboration, Exploiting the Ubiquitin System to Target the ‘Undruggable’ Cancer Proteome, is funded by a Swedish Research Council Project Grant under the Italy–Sweden programme.

Publication

Beneath the surface: Hidden degrons and untapped ligases for molecular glue degrader discovery.
Brunner A, Lauriola A, Guardavaccaro D, Sangfelt O.  
Molecular Cell, 19 November 2026.